RecruitingPhase 2NCT06644534
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
Studying MELAS
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Thiogenesis Therapeutics, Inc.
- Principal Investigator
- Patrice P Rioux, MD, PhDThiogenesis Therapeutics, Inc.
- Intervention
- TTI-0102(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- Angers University Hospital Center (CHU Angers), Angers, France
- Radboud University Medical Center, Nijmegen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06644534 on ClinicalTrials.govOther trials for MELAS
Additional recruiting or active studies for the same condition.